$-0.57 EPS Expected for RedHill Biopharma Ltd. (RDHL)

April 17, 2018 - By Migdalia James

RedHill Biopharma Ltd. (NASDAQ:RDHL) Logo

Analysts expect RedHill Biopharma Ltd. (NASDAQ:RDHL) to report $-0.57 EPS on May, 2.They anticipate $0.07 EPS change or 14.00 % from last quarter’s $-0.5 EPS. After having $-0.50 EPS previously, RedHill Biopharma Ltd.’s analysts see 14.00 % EPS growth. The stock increased 0.40% or $0.02 during the last trading session, reaching $4.96. About 157,983 shares traded or 102.77% up from the average. RedHill Biopharma Ltd. (NASDAQ:RDHL) has declined 50.83% since April 17, 2017 and is downtrending. It has underperformed by 62.38% the S&P500.

RedHill Biopharma Ltd. (NASDAQ:RDHL) Ratings Coverage

Among 2 analysts covering RedHill Biopharma (NASDAQ:RDHL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma had 2 analyst reports since November 14, 2017 according to SRatingsIntel. The stock has “Buy” rating by Roth Capital on Tuesday, November 14.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company has market cap of $109.39 million. The firm promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. It currently has negative earnings. The Company’s clinical-stage pipeline includes TALICIA , an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S.

RedHill Biopharma Ltd. (NASDAQ:RDHL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: